All News
ACR22: Polymyalgia Rheumatica in the Spotlight
One of the enduring legacies of ACR 2022 for me will be the emphasis on polymyalgia rheumatica (PMR). Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run in this space. Read on for a quick PMR-roundup from the meeting!
Read ArticleDo biologics help taper steroids in Adult Still’s Disease?
A Japanese large scale claims data study was able to collect 5-year data to study the treatment patterns in Still’s. In May 2019, intravenous tocilizumab was approved in Japan for Still’s disease. The study was designed to see patterns of steroid exposure before and after the approval of this therapy.
Read ArticlePolymyalgia rheumatica: more than just steroids at ACR22
After decades of having little else proven apart from glucocorticosteroids with which to treat polymyalgia rheumatica (PMR), evidence for steroid-sparing options has grown in recent years, and this crescendo is set to continue at ACR Convergence 2022 in Philadelphia, PA.
Read ArticleIndustry Abstract Previews of ACR 2022
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do list.
Read ArticleNew 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis
The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent developments and perspectives in RA treatment.
Read ArticleACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs
New research being presented this week at ACR Convergence 2022, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a combination of conventional and biologic DMARDs compared with other consensus treatment plans by the Childhood Arthritis and Rheumatology Research Alliance (CARRA).
Read Article2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections
A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).
Read ArticleLinks:
Links:
Links:
Heavy Metal Rheumatology (9.23.2022)
Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Links:
Is PMR the Next Indication for Tocilizumab?
About half of patients with steroid-dependent polymyalgia rheumatica (PMR) were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, which also improved disease control in most cases, a randomized phase III trial showed.
Read Article